Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / IMPDH2

IMPDH2

Basics

Aliases:
This biomarker is also known as:
  • IMP (inosine monophosphate) dehydrogenase 2,
  • IMPDH 2,
  • inosine monophosphate dehydrogenase type II,
  • IMPD2,
  • IMP (inosine 5'-monophosphate) dehydrogenase 2,
  • inosine 5' phosphate dehydrogenase 2,
  • IMPDH,
  • IMPD 2,
  • EC 1.1.1.205,
  • inosine-5'-monophosphate dehydrogenase 2,
  • IMPDH-II,
  • IMP oxireductase 2,
  • IMP dehydrogenase 2,

View in BioMuta

Description…

The enzyme IMPDH2 catalyzes the rate-limiting step of conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed step in the de novo synthesis of guanine nucleotides. Therefore IMPDH2 is involved in maintaining cellular guanine deoxy- and ribonucleotide pools needed for DNA and RNA synthesis. It is also thought to be involvedmin the development of malignancy and the growth progression of some tumors.

Attributes

QA State: Under Review
Type: Protein
Short Name:
HGNC Name: IMPDH2

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.